What’s the preferred breast cancer screening modality? When should patients begin screening mammograms? Are guidelines being considered? We compiled the data.
[[{"type":"media","view_mode":"media_crop","fid":"25331","attributes":{"alt":"","class":"media-image","id":"media_crop_2606298220343","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2310","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em;","title":" ","typeof":"foaf:Image"}}]]
The breast cancer screening debate is ongoing, but the results of our 2014 Breast Cancer Screening Survey are in. We polled readers from Diagnostic Imaging and obgyn.net to see what clinicians are using and recommending for breast cancer screening.
As expected, mammography is the most preferred method of screening. Part of the controversy about breast cancer screening is the recommended age of biennial screening for average-risked women, which the United States Preventive Services Task Force (USPSTF) recommends beginning at age 50, however, almost half of our respondents recommend beginning biennial screening at age 40. The USPSTF is in the process of updating their recommendations, which reconsiders the recommended age to begin screening and the effectiveness of screening based on modality.
Almost all respondents (91 percent) recommend supplemental screening for women at high-risk of breast cancer. Ultrasound was the supplemental modality of choice for 37 percent of the respondents, with MRI coming close behind at 35 percent.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.